Discover
STOK
Stoke Therapeutics, Inc.
28.43
2 x 20.52
2 x 36.22
bid
ask
-
0.50
1.73%
2 @ 04:00 PM
28.43 +0.00 (0.00%)
| Ytd | -10.43% | |
| 1y | 20.98% |
28.01
day range
28.91
20.32
52 week range
40.22
| Open | 28.85 | Prev Close | 28.93 | Low | 28.01 | High | 28.91 | Mkt Cap | 1.83B |
| Vol | 1.56M | Avg Vol | 885.35K | EPS | -3.39 | P/E | N/A | Forward P/E | -8.09 |
| Beta | 1.23 | Short Ratio | 11.42 | Inst. Own | 123.61% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 30.52 | 200-d Avg | 31.93 | 1yr Est | 46.46 |
STOK News
defenseworld.net
Squarepoint Ops LLC Acquires Shares of 29,310 Stoke Therapeutics, Inc. $STOK
Squarepoint Ops LLC acquired a new position in Stoke Therapeutics, Inc. (NASDAQ: STOK) in the second
businesswire.com
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
benzinga.com
Stoke, Biogen Report Lasting Seizure Reductions In Dravet Syndrome Study
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expre
benzinga.com
Stoke Therapeutics, Biogen Present Data On Zorevunersen As Treatment For Dravet Syndrome At 16th Eur
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expre
benzinga.com
JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price Target
JP Morgan analyst Jessica Fye reinstates Stoke Therapeutics (NASDAQ:STOK) with a Overweight and a